2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Longitudinal digital observation of the holistic quality of the life of patients with Parkinson’s disease

F. Thieken, A. Greuel, L. Timmermann, K. Sohrabi, C. Woopen, B. Schmitz-Luhn, A. Janhsen, C. Eggers (Marburg, Germany)

Quality of Life  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Longitudinal DNA methylation changes, in blood, associated with Parkinson’s disease progression

A. Henderson, K. Fisch, J. Hua, E. Driver-Dunckley, C. Sherzer, P. Desplats, T. Dunckley (Tempe, AZ, USA)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Looking “cherry red spot myoclonus” in the eyes

GM. Riboldi, J. Martone, JR. Rizzo, T. Hudson, S. Frucht, J. Rucker (New York, NY, USA)

Rare Genetic and Metabolic Diseases  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Lower urinary tract symptoms and urodynamic findings in SCAs

M. Jang, H. Kim, B. Jeon, A. Kim (Jeonju, Republic of Korea)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

LRP10 variants and Parkinson’s disease in the Chinese population

JN. Foo, E. Chew, M. Lian, M. Tandiono, EK. Tan (Singapore, Singapore)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset

A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

Neuropharmacology  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)

B. Leavitt, R. Reilmann, M. Gordon, K. Anderson, A. Feigin, S. Tabrizi, J. Stout, P. Piccini, B. Russell-Schulz, A. Mackay, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Vancouver, BC, Canada)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection

F. Rakhimov, B. Sultanov (Tashkent, Uzbekistan)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Management of Patients with Functional Movement Disorders: A Transcultural Perspective

C. Maurer, D. Anderson, A. Asadi-Pooya, J. Baizabal, M. Damianova, C. Ganos, R. Kanaan, M. Tijssen, J. Kwasa, I. Moreno, S. Pandey, JE. Park, D. Saylor, M. Stamelou, C. Stephen, T. Teodoro, M. Tinazzi, K. Lafaver (Stony Brook, NY, USA)

Functional (Psychogenic) Movement Disorders  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

MDS Rare Movement Disorders Study Group Global Genetic Testing Survey: exploring the unmet needs

R. Walker, H. Jinnah, M. Rodriguez Violante, C. Gonzalez, E. Gatto (New York, NY, USA)

Rare Genetic and Metabolic Diseases  ·  Les Muses Terrace, Level 3